Successful Completion of Dose Escalation at the First Dose Level in Ongoing Phase 1 Trial of GLB-002 in Patients with R/R NHL
FEB 23, 2024
San Diego, California, Feb 23, 2024 – GluBio Therapeutics Inc., a clinical-stage, TPD-focused biotech company announced the successful completion of the first Safety Review Committee (SRC) meeting for phase 1 clinical trial of GLB-002, a next-generation IKZF1/3 selective molecular glue degrader, in patients with relapsed or refractory non-Hodgkin lymphoma (R/R NHL). In cohort 1, GLB-002 exhibited excellent pharmacokinetics, pharmacodynamics, safety and tolerability, and achieved the expected extent of IKZF1/3 degradation. The cohort 2 is now open for patient recruitment, which marks the entry of this clinical trial into a new stage. “We are very delighted that we have successfully completed the dosing and Dose Limiting Toxicities ( DLT ) observation for cohort 1 within 2 months of study kickoff for the GLB-002 phase 1 study, to begin evaluating its safety and preliminary efficacy at the next dose level.” said Gang Lu, Ph.D., Founder, President and CEO of GluBio Therapeutics, “GLB-002 is
Read More
GluBio Therapeutics Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs
AUG 01, 2022
GluBio Therapeutics Raises Nearly $50 Million in Series A Round to Work on Molecular Glue Degraders
MAR 07, 2022
GluBio Therapeutics Announced the Closing of $20 Million Seed Financing Round from Three Founding Investors
MAR 15, 2021
GluBio Therapeutics Was Founded by Two Prominent Leaders in the Field of Targeted Protein Degradation
MAR 01, 2021